Nikolai N. Semenov

Nikolai N. Semenov

Auto-generated profile, based on publicly available information

Nikolai N. Semenov

A.S. Loginov Moscow Medical Scientific Center, Moscow City Health Department; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2022 in Almanac of Clinical Medicine
Verified
Journal Article
Open access
PDF file
OAOlga V. Andreeva
Olga V. Andreeva
NSNikolai N. Semenov
Nikolai N. Semenov
DSDmitri Shchekochikhin
Dmitri Shchekochikhin
ANAlena Novikova
Alena Novikova
NPNadezhda Potemkina
Nadezhda Potemkina
ПГПолтавская Мария Георгиевна
Полтавская Мария Георгиевна
Background: Endothelial dysfunction is recognized as one of the early markers of cardiovascular disorders. It is supposed to be a potential predictor of cardiovascular complications in patients receiving adjuvant and neoadjuvant chemotherapy. Aim: To estimate the prevalence of endothelial dysfunction in solid cancer patients compared to that in individuals without any malignancies. Materials and methods: This observational study included 74 patients with solid malignancies, mostly gastrointestinal. Prior to polychemotherapy, all patients were examined for endothelial function of small and large arteries (AngioScan-01, Fiton, Russia) and peripheral artery stiffness (pulse wave contour analysis and occlusion test). The results were compared with those of the Russian population trials of endothelial dysfunction – Meridian-RO (Ryazan region) and trial in the rural population of the Krasnodar region. Results: Compromised vasodilation and smaller arteries tone were found in 64.9% (48/74) of the cancer patients, while impaired vasodilation of larger muscular arteries was present in 94.6% (70/74) of the patients. According to the Meridian-RO trial in the Ryazan region, endothelial dysfunction had been found in 51.2% (n = 341) of women and 52.4% (n = 300) of men, whereas the Krasnodar regional population data had shown it in 68.4% (n = 353) of women and 71.7% (n = 253) of men. Conclusion: The prevalence of endothelial dysfunction in the patients with solid malignancies, who have not undergone any chemo- or radiation therapy, is significantly higher than in the population of comparable age, conventional cardiovascular risk factors, and comorbidities. No significant increase of vascular stiffness was identified.

22 January 2025 in Voprosy onkologii
Verified
Journal Article
Open access
НСНиколай Николаевич Семёнов
Николай Николаевич Семёнов
МФМихаил Юрьевич Федянин
Михаил Юрьевич Федянин
ИХИгорь Евгеньевич Хатьков
Игорь Евгеньевич Хатьков
ЛЖЛюдмила Григорьевна Жукова
Людмила Григорьевна Жукова
ДСДаниил Львович Строяковский
Даниил Львович Строяковский
IPIlya A. Pokataev
Ilya A. Pokataev
Введение. В настоящее время во II линии лечения метастатического рака желудка используются различные комбинации лекарственных препаратов. Цель. Сравнить выживаемость без прогрессирования (ВБП) и общую выживаемость (ОВ) у пациентов метастатическим раком желудка, получавших различные варианты терапии во II линии лечения. Материалы и методы. Из регистра Москвы выделено 384 пациента с морфологически подтвержденным метастатическим раком желудка, у которых было зафиксировано прогрессирование на фоне проведения I линии лечения. Сформированы 3 группы: получавшие терапию ингибиторами контрольных точек иммунитета (ИКТ) (n = 93), химиотерапию (х/т) (n = 82) и химиотерапию + рамуцирумаб (х/т + раму) (n = 208). Лечение проводилось с 2018 по 2023 гг. Медиана времени наблюдения составила 35,8 мес. Результаты. В общей группе отмечено преимущество по ВБП у больных, получавших ИКТ и х/т + раму (4,3 мес. и 5,1 мес. соответственно), по сравнению с группой х/т (4,0 мес., р = 0,019 и 0,056 соответственно). ОВ во всех трех группах не различалась (ИКТ — 8,5 мес., х/т — 10,1 мес., х/т + раму — 10,7 мес., р = 0,4 и 0,43, в сравнении с группой х/т). Уровень CPS не влиял на эффективности в группе ИКТ (ВБП при CPS 0-9 — 3,9 мес. при CPS≥10 — 4,2 мес., р = 0,61; ОВ 6,6 мес. и 6,9 мес. соответственно, р = 0,875). При наличии MSI (n = 27) в группе ИКТ в сравнении с MSS ВБП была 11,1 мес. против 3,9 мес., р = 0,068, ОВ — 14,2 мес. против 5,4 мес., р = 0,162. При сравнении с больными с MSI, получавших х/т + раму (n = 14) эти различия нивелировались (ВБП — 11,1 мес. и 3,8 мес., р = 0,13, ОВ — 14,2 мес. и 16,0 мес., р = 0,75). В группах х/т + раму использование двух цитостатиков в сравнении с монотерапией улучшало ВБП, но не ОВ (ВБП — 5,8 мес. и 4,0 мес., р = 0,009, ОВ — 10,8 и 10,1 мес., р = 0,79). При проведении псевдорандомизации отмечено сохранение результатов, полученных в общей группе. Выводы. Дублетные комбинации, добавление рамуцирумаба или использование ИКТ не продемонстрировали улучшение результатов в сравнении с монохимиотерапией.

15 April 2025 in Malignant tumours
Verified
Journal Article
Open access
PDF file
NSN. N. Semenov
N. N. Semenov
MFMikhail Fedyanin
Mikhail Fedyanin
LZLiudmila Zhukova
Liudmila Zhukova
IKI. E. Khatkov
I. E. Khatkov
DSD. L. Stroyakovskii
D. L. Stroyakovskii
МФМ. Ю. Федянин
М. Ю. Федянин
Introduction: the use of immunotherapy agents in combination with chemotherapy has shown its effectiveness in randomized trials for the first-line treatment of metastatic gastric cancer. The paper considers the experience of the Moscow oncological service in evaluating the effectiveness of pembrolizumab and nivolumab in patients with metastatic gastric cancer, depending on morphological (CPS, MSI) characteristics.Aim of the study: to compare progression-free survival (PFS) and overall survival (OS) in patients with advanced gastric cancer who underwent immunotherapy (as monotherapy or in combination with chemotherapy) or standard chemotherapy with oxaliplatin and fluoropyrimidines.Patients and methods: 194 patients met the inclusion criteria. Of these, 52 patients received checkpoint inhibitors (ICI) (18-immunotherapy alone; 31-in combination with chemotherapy, 15 patients received pembrolizumab and 37 patients received nivolumab); 142 patients received chemotherapy CAPOX or FOLFOX without ICI. The median follow-up was 29.5 months (17.4–62 months). Males were 55.8 % and 57.7 % with average age of 64.5 and 65.9 years, ECOG 2 was detected in 15.4 % and 8.5 % of patients. Other characteristics were also comparable: CPS > 10 69.2 % and 19.7 % (p = 0.0001), MSI 26.2 % and 4.9 % (p = 0.009), 2nd lines and further treatment were received by 36.5 % and 69.3 % (p = 0.0001), respectively.Results: in the entire population PFS was 7.9 months and 6.4 months (HR 0.46; 95 % CI 0.32–0.67, p = 0.0001), and OS was 17.3 months and 14.6 months (HR 0.71; 95 % CI 0.49–1.04, p = 0.076), respectively. The univariate analysis showed that only 1 prognostic factor for survival — the number of organs with metastases. In accordance with this, in case of the presence of metastases in 1–2 organs the use of ICI had an advantage in terms of PFS (p = 0.051 and p = 0.001), while in case of 3 or more organs involved there was no advantage (p = 0.62). Assessing the effect of the CPS level in patients with MSS phenotype, it was shown that at CPS0–9 there was no advantage in PFS (6.1 months and 6.9 months, p = 0.7) and OS (8.8 months and 14.9 months, p = 0.39). With CPS > 10, an advantage was noted when adding ICI for PFS (9.9 months and 4.4 months, p = 0.0001), and OS 18.2 months and 12.1 months (p = 0.23). However, the results did not differ at the CPS level > 50. When evaluating patients with MSI, we demonstrated that with a median PFS of 6.6 months and 5.2 months, respectively (HR 0.48; 95 % CI 0.17–1.4; p = 0.165), the median OS in patients who received ICI with or without CT was significantly higher — 24.3 months and 11.1 months, respectively (HR 0.4; 95 % CI 0.13–1.21; p = 0.11).Conclusions: the use of ICI in the first line therapy for metastatic gastric cancer (compared with CT alone) increases the proportion of patients living without progression for 12 months or more, and the overall survival rate was also increased by more than 2 times. The threshold level of CPS for ICI assignment needs to be > 10. The relationship between the effectiveness of immunotherapy and PD-L1 expression in gastric cancer with MSI tumors requires further study in a larger sample of patients. Information at the CPS level, the presence of MSI and HER2 / neu should be presented at the time of discussion of treatment tactics at the onset of metastatic disease.

17 December 2024 in Malignant tumours
Verified
Journal Article
Open access
PDF file
MGM. A. Gorshkova
M. A. Gorshkova
NSN. N. Semenov
N. N. Semenov
MDM. A. Danilov
M. A. Danilov
OVO. S. Vasnev
O. S. Vasnev
YKYu. V. Kulezneva
Yu. V. Kulezneva
VPV. A. Prosikov
V. A. Prosikov
Introduction: Recent studies of neoadjuvant therapy for colon cancer indicate a significant percentage of patients’ retreatment, more likely due to the low accuracy of radiation diagnostics. The new Node-RADS lymph node assessment system can allow for more accurate selection of patients for neoadjuvant chemotherapy. Currently, the efficiency of adjuvant chemotherapy has been reliably substantiated for N1 within three months, for N2 within 6 months, for NO-only in the presence of negative prognosis factors. This allows us to study the applicability of neoadjuvant chemotherapy with high reliability of lymph node involvement according to computed tomography data in the preoperative period.Study objective: To determine the diagnostic efficiency of the Node-RADS system for predicting the risk of metastatic lymph node involvement in colon cancer patients.Materials and methods: A retrospective comparative analysis of computed tomography and pathomorphological examination data was performed for 75 colon cancer patients operated on at the M. N. A. S. Loginov in the period from 2021 to 2023. The clinical stage was routinely established based on the results of computed tomography of the chest and abdomen with intravenous contrast. Restaging was performed in the same patients according to the Node-RADS system with a lymph node score of 1-5 points. The results of two radiation diagnostic methods were compared with the data of the pathomorphological examination of the surgical material.Results: The accuracy (AUC) of computed tomography in the routine diagnostic method was 0.69. According to Node-RADS assessment, lymph nodes of 4-5 points were considered involved. Statistical analysis showed that the accuracy of this method increased significantly (AUC0.93). To determine the differences between the results of routine assessment, Node-RADS and the pathomorphological examination results, we found statistically significant (p < 0.0001) differences between the routine assessment and the results of pathomorphology, which corresponded to a low diagnostic value. At the same time, when comparing the results of the assessment according to Node-RADS and the conclusion of the pathomorphological study, no statistically significant differences were found (p = 0.109), which corresponded to sufficient diagnostic value of assessing the metastatic regional lymph nodes according to the Node-RADS criteria.Conclusions: The Node-RADS system, presented as a universal system for assessing malignant lymph nodes shows a fairly high diagnostic potential.

10 August 2023 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
IKIgor E. Khatkov
Igor E. Khatkov
NSNikolai N. Semenov
Nikolai N. Semenov
RIRoman E. Izrailov
Roman E. Izrailov
MEMikhail Efanov
Mikhail Efanov
KDKamil D. Dalgatov
Kamil D. Dalgatov
LZLiudmila Zhukova
Liudmila Zhukova
Background. Currently available data on the efficacy and indications for neoadjuvant chemotherapy in patients with primary resectable pancreatic cancer are contradictory and not clearly defined. Aim. To conduct a comparative assessment of the effectiveness of neoadjuvant chemotherapy and primary surgical treatment followed by adjuvant chemotherapy in patients with primary resectable pancreatic cancer. Materials and methods. In our study, the efficacy of neoadjuvant chemotherapy was retrospectively evaluated in 45 patients and in 153 patients with primary surgical treatment and subsequent adjuvant chemotherapy. Results. With a median follow-up of 41.7 months. Both, recurrence free survival in the group of patients receiving neoadjuvant chemotherapy followed by surgical treatment (n=33; 73%) and in the group with surgical treatment and subsequent adjuvant chemotherapy (13.9 and 19.5 months; p=0.35) and overall survival (28.4 months vs 33.7 months; p=0.29) were no different. The CA level of 19.9500 IU/ml in the neoadjuvant chemotherapy group was observed in 20 (44.4%) patients. At the same time, surgical treatment was performed only in 11 (55%) patients. At the same time, at the CA 19.9 level 500 IU/ml, at the end of neoadjuvant chemotherapy, surgical treatment was not performed in only 3 (12%) patients (p=0.005). Conclusion. The long-term results of treatment of patients with primary resectable pancreatic cancer, whose first stage was neoadjuvant chemotherapy, practically do not differ from the group whose treatment began with surgery. Treatment of patients with an initially high (500 IU/ml) level of CA 19.9 is preferable to start with neoadjuvant chemotherapy. Patients who may have doubts about the likelihood of adjuvant chemotherapy (general condition, social adaptation, place of residence), it is also preferable to start treatment with neoadjuvant chemotherapy. It is necessary to change the algorithm of examination of patients, especially those with a level of CA 19.9500 IU/ml, to exclude a greater prevalence, for example, performing diagnostic laparoscopy to exclude metastases in the peritoneum.

15 March 2024 in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
Verified
Journal Article
Open access
PDF file
LZLiudmila Zhukova
Liudmila Zhukova
RIR. E. Izrailov
R. E. Izrailov
NSN. N. Semenov
N. N. Semenov
MMM. V. Mikhnevich
M. V. Mikhnevich
IKI. E. Khatkov
I. E. Khatkov
   Aim. To evaluate long-term oncological outcomes of pancreatoduodenectomy in resectable pancreatic head cancer in patients over 70 years of age.   Materials and methods. A retrospective analysis of the Moscow Clinical Scientific Center registry revealed 63 patients aged > 70 years with resectable pancreatic head cancer. In 2016–2023, these patients underwent pancreatoduodenectomy. Males accounted for 35 %, and the median age comprised 75 years. Stage II was diagnosed in 44.4 % of patients, stage I – in 31.7 %, and stage III – in 23.8 %. Median follow-up accounted for 34.5 months. The authors analyzed the effect of patient characteristics, tumor, perioperative data and method of surgery on overall survival.   Results. Adjuvant chemotherapy (p = 0.005; HR 0.28, CI 0.115–0.62) and low preoperative albumin levels (p = 0.004; HR 0.203, CI 0.28–0.61) had a significant impact on overall survival. After open surgery, 56 % of patients did not receive adjuvant chemotherapy, after minimally invasive surgery – 15.4 % (p = 0.0001).   Conclusion. Minimally invasive pancreatoduodenectomy reveals no negative effect on the oncological outcomes of treatment for resectable pancreatic head cancer in patients ≥ 70 years old. Adjuvant chemotherapy and hypoalbuminemia prior to surgery are considered to be statistically significant factors influencing overall survival. Minimally invasive techniques enable adjuvant chemotherapy to be administered to a larger number of patients compared to open intervention.